NEW YORK – Genomics-based infectious disease diagnostics maker Biotia announced on Monday that the New York State Department of Health's Clinical Laboratory Evaluation Program has authorized its Biotia-ID laboratory-developed test for urinary tract infections.
Biotia-ID uses artificial intelligence and shotgun metagenomic sequencing to identify pathogens that can cause UTIs. It is the first genomics-based urine assay leveraging AI to be approved by the NYSDOH, the firm said in a statement.
"By providing accurate, detailed, and timely information, we can move towards a future where treatment is truly personalized and public health is protected," Niamh O'Hara, CEO and cofounder of Biotia, said in a statement.
The Biotia-ID test is now listed in the New York state LDT database.
"This approval will enable us to offer access to this vital technology, ensuring that patients and clinicians in New York, and soon across the United States, have access to the most accurate and comprehensive diagnostic information available," said Dorottya Nagy-Szakal, chief medical officer at Biotia, adding that the ultimate goal is to support responsible use of antimicrobials and improve patient outcomes.
Biotia said it is working with medical institutions and laboratories to integrate its product into clinical workflows, as well as with insurance providers to ensure that Biotia-ID is accessible to patients.